Titan Biotech Ltd (524717)
Certificate under Regn 74(5) of SEBI (DP) Regulations, 2018 for quarter ended September 30, 2026
Certificate under Reg. 74(5) of SEBI (DP) Regulations for Q2 FY27 submitted
- Securities dematerialization confirmed for quarter ended Sep 30, 2026
- Certificates mutilated and cancelled after verification
- Depository names updated in register within 15 days
- Securities listed on stock exchanges as per earlier issues
- Confirmation received from Registrar & Share Transfer Agent
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 524717 — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add 524717 to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Titan Biotech Ltd
Important.
The summary above is generated automatically from Titan Biotech Ltd's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.